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Mark J. Osborn1, Troy C. Lund1, Alain Hovnanian2,3, John E. Wagner1 and Bruce R. Blazar1
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited blistering skin disorder caused by mutations
in the COL7A1 gene-encoding type VII collagen (Col7), the major component of anchoring fibrils at the
dermal–epidermal junction. Individuals with RDEB develop painful blisters and mucosal erosions, and currently,
there are no effective forms of therapy. Nevertheless, some advances in patient therapy are being made,
and cell-based therapies with mesenchymal and hematopoietic cells have shown promise in early clinical trials.
To establish a foundation for personalized, gene-corrected, patient-specific cell transfer, we generated induced
pluripotent stem (iPS) cells from three subjects with RDEB (RDEB iPS cells). We found that Col7 was not required
for stem cell renewal and that RDEB iPS cells could be differentiated into both hematopoietic and
nonhematopoietic lineages. The specific epigenetic profile associated with de-differentiation of RDEB
fibroblasts and keratinocytes into RDEB iPS cells was similar to that observed in wild-type (WT) iPS cells.
Importantly, human WT and RDEB iPS cells differentiated in vivo into structures resembling the skin. Gene-
corrected RDEB iPS cells expressed Col7. These data identify the potential of RDEB iPS cells to generate
autologous hematopoietic grafts and skin cells with the inherent capacity to treat skin and mucosal erosions
that typify this genodermatosis.
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INTRODUCTION
The severe blistering disease recessive dystrophic epidermo-
lysis bullosa (RDEB) is caused by loss-of-function mutations
in the type VII collagen gene, COL7A1 (Shimizu et al., 1996;
Varki et al., 2007; Dang and Murrell, 2008). Type VII colla-
gen (Col7) deficiency is responsible for diminished or
absent formation of homotrimers of Col7, necessary to form
anchoring fibrils that normally insert into the lamina densa of
the skin basement membrane and to provide adhesion to
interstitial dermal collagen. Without anchoring fibrils, skin
integrity is lost and blistering occurs below the lamina densa.
Individuals with RDEB exhibit extensive painful trauma-
induced skin and mucosal blisters and erosions. Owing to
extreme skin fragility, recurrent injury, and aberrant tissue
repair, subjects with severe generalized RDEB are prone to
develop esophageal strictures, mutilating scarring, pseudo-
syndactyly, joint contractures, and highly malignant skin
squamous cell carcinomas (Fine et al., 2008). Until recently,
treatment options have been limited to palliative measures,
such as analgesia, bandaging, nutritional support, esophageal
dilatation, and treatment of infections (Mellerio et al., 2007;
Abercrombie et al., 2008). At present, however, several
promising interventions are being developed, including
systemic interventions using gene therapy, protein therapy,
and cellular transplantation (Chen et al., 2002; Mecklenbeck
et al., 2002; Ortiz-Urda et al., 2002, 2003; Fivenson et al.,
2003; Woodley et al., 2004a, b, 2007; Ferrari et al., 2006;
Chino et al., 2008; Wong et al., 2008; De Luca et al., 2009;
Tolar et al., 2009; Conget et al., 2010; Yan and Murrell,
2010). Cellular transplantation studies using mesenchymal
stem cells or hematopoietic stem and progenitor cells have
been shown to provide a source of normal donor Col7 and to
ameliorate many of the disease manifestations (Chino et al.,
2008; Tolar et al., 2009; Conget et al., 2010). However, these
therapies have focused on using allogeneic cells, which may
be targeted for elimination by the host immune system. In
addition, for allogeneic hematopoietic cell transplantation,
potentially toxic chemoradiotherapy and immunesuppressive
agents need to be used to prepare the host to receive the
allogeneic donor graft.
Patient-specific stem cells, such as the recently identi-
fied induced pluripotent stem (iPS) cells (Takahashi and
Yamanaka, 2006a; Yu et al., 2007; Park et al., 2008b),
present an opportunity to use the progeny of autologous
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rather than allogeneic cells to correct RDEB. An advantage of
gene-corrected autologous RDEB iPS cells is the possibility of
simultaneously deriving Col7-producing ectodermal tissues
(such as the skin) and mesodermal tissues (such as hemato-
poietic stem and progenitor cells). As the systemic use of
bone marrow and cord blood transplantation combined with
local injections of skin fibroblasts (FBs) may be synergistic
in the wound treatment of RDEB patients, autologous
gene-corrected iPS cells would represent a robust approach
to RDEB treatment by providing a virtually limitless supply
of both cell types, while avoiding the need for potent
immunesuppressive therapy to prevent an allogeneic immune
response. Induction of iPS cells from RDEB subjects may
also provide a means of better understanding the sequence of
downstream events initiated by Col7 deficiency during the
development of epithelial stem and progenitor cells, as well
as their progeny, as assayed both in vitro and in vivo. Such
knowledge may lead to innovative treatment approaches that
could benefit individuals with RDEB, other related inherited
skin diseases, and perhaps additional extracellular matrix
disorders.
In this study, we show that iPS cells can be obtained from
both skin FBs and keratinocytes (KCs) of individuals with
RDEB (RDEB iPS cells). We report that RDEB iPS cells can be
differentiated into both hematopoietic and nonhematopoietic
cells. These data underscore the potential of RDEB iPS cells in
modeling RDEB in the development and future use of gene-
corrected RDEB iPS cells to generate autologous hemato-
poietic grafts for systemic therapy, as well as generating skin
cells with the potential to treat individual skin and mucosal
lesions that underscore RDEB.
RESULTS
RDEB iPS cells can be generated from both FBs and KCs
Col7 can be secreted by both FBs and KCs. Therefore,
as both cell phenotypes are likely to be relevant to
RDEB pathogenesis, we isolated FBs and KCs from the skin
of three individuals with RDEB (Table 1). The cultured
primary FBs and KCs had the characteristic spindle-shaped
and cobblestone appearances, respectively and, as expec-
ted, KCs expressed Col7, type XVII collagen, keratin 1 (K1),
keratin 5 (K5), and keratin 15 (K15) (Supplementary Figure
S1 online).
To derive RDEB iPS cells, RDEB FBs (from patient 1 (P1)
and patient 3 (P3)) and RDEB KCs (from patient 2 (P2) and P3)
(Table 1) were transduced with retroviral vectors carrying
four known reprogramming transcription factors (namely
OCT4, SOX2, KLF4, and c-MYC), which are typically
associated with pluripotency. Transduced cells were cultured
on a supportive stroma of irradiated murine embryonal
fibroblasts (MEFs). After 6–7 weeks, flat colonies of RDEB iPS
cells with clear-cut, round edges emerged from the two-
dimensional MEF culture (Figure 1a–o). Although both FBs
and KCs have been used successfully to generate iPS cells,
KCs have been preferred by some because they appeared to
reprogram faster than FBs (Maherali et al., 2008a). All iPS
colonies in this study, however, appeared 45±4 days after
viral transduction, and with roughly similar efficiency in FB
and KC cultures (Table 1).
When compared with parental RDEB KCs, RDEB iPS
cells showed persistent mRNA expression of SOX2, used for
reprogramming, as well as genes associated with pluripo-
tency in iPS cells (such as NANOG, LIN28, and DNMT3b).
Moreover, there was transient mRNA expression of OCT4,
c-MYC, and KLF4, used to accomplish reprogramming.
The mRNA profile seen in RDEB iPS cells is as would
be expected to occur in wild-type (WT) iPS (WT iPS) cells
(Figure 1p and q). RDEB iPS cells also expressed protein
markers characteristic of reprogrammed iPS and embryonic
stem cells: TRA-1-81, stage-specific embryonic antigens-3
and -4, OCT4, and NANOG (Figure 2 and Supplementary
Figures S2 and S9 online).
These reprogramming factors are believed to activate a
network of transcriptional factors, which in turn induce
epigenetic changes (Freberg et al., 2007; Aasen et al., 2008;
Okita et al., 2008; Maherali et al., 2008a; Park et al., 2008a).
Therefore, we used bisulfite sequencing to confirm the
methylation status of OCT4 and NANOG promoters in RDEB
iPS cells. A methylated pattern is indicative of gene silencing,
whereas an unmethylated pattern indicates the potential for
robust gene expression. Individual colonies of cells from
RDEB iPS cells were analyzed by bisulfite sequencing that
showed a pattern characteristic of iPS cells in which OCT4
and NANOG promoter sequences are unmethylated. In
contrast, mature progeny such as FBs and KCs had the
expected pattern of both methylated and unmethylated
Table 1. Patient and iPS cell characteristics
Patient Type VII collagen mutations Age (years) Cell type
Number of iPS colonies
per 100,000 cells
P1 c.6176A4G (p.Glu2059Gly) IVS5+1G4A 6.2 FB 3
P2 c.4919delG (p.Gly1640fsX70)
c.8254_8255delAG (p.Arg2751fsX20)
6.9 KC 7
P3 c.6781C4T (p.Arg2261X) IVS110-1 G4C 14.5 FB 2
P3 c.6781C4T (p.Arg2261X) IVS110-1 G4C 14.5 KC 2
WT NA 9 KC 2
Abbreviations: FB, fibroblast; iPS, induced pluripotent stem; KC, keratinocyte; NA, not applicable; P, patient.
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sequences (Park et al., 2008b; Raya et al., 2009) (Figure 3 and
Supplementary Figure S3 online).
Both RDEB FB- and RDEB KC-derived RDEB iPS cells from
the three individuals, as well as the one WT control, had
normal female karyotypes as determined by high-resolution
chromosomal G-banding (Supplementary Figure S4 online
and data not shown). As the purity of iPS cultures is critical
for our downstream experimentation, we formally demon-
strated a lack of contamination of stromal cell (MEF) feeder
cells used to generate RDEB iPS cells. Competitive PCR of
variable number tandem repeats indicated that all RDEB iPS
cell lines were fully host derived (data not shown).
Collectively, the transcription profile and cellular phenotype
of RDEB iPS cells from all subjects were consistent with
morphological and phenotypical gain of pluripotency.
RDEB iPS cells widely differentiate in vivo
To provide further evidence of the identity of iPS cells on a
functional level, KC-derived RDEB iPS cells were injected
intramuscularly into immunedeficient mice. Within 6–8
weeks, well-differentiated cystic teratomas were observed,
confirming the phenotype-defining ability of iPS cells to
differentiate in vivo into a wide array of cell lineages
encompassing cells of endodermal, mesodermal, and ecto-
dermal origins (Figure 4).
RDEB iPS cells differentiate into hematopoietic cells
As we have shown that cells contained in the bone marrow
and cord blood can home to RDEB skin and produce Col7,
one of the mesodermal lineages, hematopoietic lineage, is
directly relevant to our ultimate goal of generating gene-
corrected cells for autologous hematopoietic cell transplanta-
tion. The hematopoietic potential of RDEB iPS cells was
tested using embryoid bodies (Supplementary Figure S5A
online). Embryoid bodies mimic early stages of embryonic
development and serve to provide three-dimensional archi-
tecture, which promotes cell differentiation. Embryoid bodies
derived from RDEB iPS cells were enzymatically dissociated
into single cells. After seeding in low-attachment dishes, cells
were induced to differentiate in medium containing human
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Figure 1. Induction of RDEB skin cells into RDEB iPS cells. (a, d, g, j, m) Live human iPS cultures stained with TRA-1-60 antibody 4 weeks after
transduction. (b, e, h, k, n) Phase-contrast image of the same iPS colonies. (c, f, i, l, o) Alkaline phophatase stain. (p) Quantitative RT-PCR analysis of OCT4,
SOX2, NANOG, KLF4, c-MYC, LIN28, and DNMT3b expression levels in RDEB KC iPS cells from P2 and P3 relative to expression levels in parental RDEB KCs
from P2 and P3. (q) Quantitative RT-PCR analysis of the same genes in WT KC iPS cells relative to expression levels in parental WT KCs. All values were
normalized against endogenous GAPDH expression. AP, alkaline phosphatase; FB, fibroblast; iPS cells, induced pluripotent stem cells; KC, keratinocyte; PC,
phase contrast; P2, patient 2; P3, patient 3; RDEB, recessive dystrophic epidermolysis bullosa; RT-PCR, reverse transcriptase-PCR; WT, wild type. Bar¼ 50 mm.
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hematopoietic growth factors: stem cell factor, Flt3 ligand,
interleukin-3, interleukin-6, granulocyte-colony-stimulating
factor, and bone morphogenetic protein 4. To define the
commitment of these cells to the hematopoietic lineage, we
assessed their capacity to function as colony-forming units.
The colony-forming capacity is a standard measure to assess
both the quality and the quantity of blood-forming stem
cells and progenitor cells. The colony-forming capacity of the
hematopoietic progeny of RDEB iPS cells was comparable
with that of the hematopoietic progeny of WT iPS cells, and
both erythroid and myeloid colonies formed (Supple-
mentary Figure S5B–D online). In addition to quantitative
measures, such as the ability to form colonies in the semisolid
medium, cells with phenotypic characteristics of myeloid
and erythroid progenitors were observed in equal distribution
on cytospins generated from WT iPS cells and RDEB iPS
cell colonies grown in a methylcellulose-enriched medium
(data not shown). In aggregate, these data confirm that
RDEB iPS cells can differentiate into cells with hematopoietic
potential.
RDEB iPS cells differentiate into skin-like structures
With our primary focus on skin pathology relevant to RDEB
subjects, we wished to identify teratoma-derived structures
resembling the skin. To delineate this ectodermal-to-skin
transition, we used staining with the K5 antibody to reveal
epidermis-like layers of KCs. Remarkably, in WT iPS cell-
derived teratomas, Col7 was expressed as a continuous band
mimicking Col7 expression at the basement membrane in the
normal skin (Figure 5a–d and Supplementary Figure S6A
online). In contrast, and consistent with Col7 deficiency in
RDEB individuals, no Col7 was detected in the skin-like
structures derived from RDEB iPS cells (Figure 5e–h and
Supplementary Figure S6B online). To demonstrate that RDEB
iPS cells can be gene corrected with exogenous Col7 DNA,
RDEB iPS cells were transfected with expression plasmid
harboring the WT human Col7 gene. Two days after
transfection, the Col7 protein was expressed in gene-
corrected RDEB iPS cultures similar to the pattern of Col7
expression observed in WT iPS cells (Supplementary Figure
S7 online). In summary, these data suggest that WT and RDEB
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Figure 2. Protein expression profile of RDEB iPS cells. To confirm their ability to express ES cell proteins, human iPS cells derived from the skin of all RDEB
patients and WT controls were immunostained with TRA-1-81 (a, g, m, s, y), SSEA-3 (c, i, o, u, aa), and SSEA-4 (e, k, q, w, ac). Corresponding images stained
with 4,6-diamidino-2-phenylindole show nuclei of individual cells in the colonies (b, h, n, t, z, d, j, p, v, ab, f, l, r, x, ad). Isotype controls are shown in
Supplementary Figure S8 online. DAPI, 4,6-diamidino-2-phenylindole; ES, embryonic stem; FB, fibroblast; iPS cells, induced pluripotent stem cells; KC,
keratinocyte; RDEB, recessive dystrophic epidermolysis bullosa; WT, wild type. Bar¼ 50mm.
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iPS cells can provide a robust system to study skin pathology
in a patient-specific manner.
DISCUSSION
To our knowledge, these are the first data to report that
autologous iPS cells can be obtained from RDEB subjects. We
found that iPS cells can be generated with a similar efficacy
of reprogramming using either skin FBs or KCs of individuals
with RDEB. These RDEB iPS cells can be induced to
differentiate into both hematopoietic and nonhematopoietic
cells. Our observation that RDEB iPS cells have the capacity
to form skin-like structures with no Col7 deposition under-
scores the potential of RDEB iPS cells in modeling RDEB in
development, in uncovering clinically relevant compensatory
changes triggered by the absence of Col7, and in the search
for effective therapeutic interventions for RDEB patients.
Relevant to this, we found that the NANOG promoter in
RDEB FBs and KCs is hypomethylated. This suggests that
increased proliferative signaling engaged in aberrant skin
repair in individuals with RDEB could, in theory, engage
cell-cycle regulation common to rapid growth, self-renewal,
and pluripotency states. Finally, we found that RDEB iPS cells
express Col7 after transfection of WT Col7. In the future,
gene-corrected RDEB iPS cells could be used not only
to generate an autologous hematopoietic graft but also to
generate nonhematopoietic skin cells with the potential to
treat individual skin and mucosal wounds. Independently
or together, these two strategies have the potential to
decrease the complications or lack of sustained improvement
observed with currently used therapies and to result in
improved survival and quality of life for individuals with
RDEB.
OCT4–2a bOCT4–4 NANOG3
WT FB WT KC
RDEB FB
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Figure 3. Epigenetic profile of RDEB iPS cells. (a) Bisulfite sequencing of theOCT4 andNANOG promoters in WT FB, RDEB FB, and FB-derived RDEB iPS cells.
(b) Bisulfite sequencing of the OCT4 and NANOG promoters in WT KC, RDEB KC, and KC-derived RDEB iPS cells. Open circles denote unmethylated
CpGs, and filled circles represent methylated CpGs. The CpG position relative to the downstream transcriptional start site is shown above each column.
Sequencing reactions of specific amplicons are represented by each row of circles. FB, fibroblast; iPS cells, induced pluripotent stem cells; KC, keratinocyte;
RDEB, recessive dystrophic epidermolysis bullosa; WT, wild type.
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Figure 4. Nonhematopoietic differentiation of RDEB iPS cells. Histological examination of mature teratoma from immunodeficient mice injected with KC
RDEB iPS cells revealed (a) a columnar epithelium of endodermal origin (arrows), (b) smooth muscle of mesodermal origin (arrows), and (c) melanocytes of
ectodermal origin (arrows). Similar mature teratomas with contribution of ectodermal-, mesodermal-, and endodermal-derived cells formed after injection
of KC WT iPS cells (data not shown). Hematoxylin–eosin stain. C, cartilage; iPS cells, induced pluripotent stem cells; KC, keratinocyte; NE, neuroectoderm;
RDEB, recessive dystrophic epidermolysis bullosa; WT, wild type. Bar¼ 50mm.
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To the best of our knowledge, this is the first described
human iPS cell model of an extracellular matrix disorder. As
RDEB iPS cells exhibit a disease-relevant phenotype, they
provide a model system to study the pathogenesis of RDEB
and related disorders. When compared with studies of
differentiated human cells and animal models of RDEB, iPS
cell studies have the added benefit of offering the opportunity
for a more extensive analysis of the cellular effects of Col7
deficiency independent of the secondary effects on systemic
inflammatory responses that would occur in vivo because of
erosions and blister formation characteristic of RDEB. As
nearly all cell types can be derived from iPS cells, analysis of
human RDEB iPS cells may have advantages over analysis of
murine animal models that are confounded by the obvious
differences in development, life span, and species-specific
consequences of cellular pathology in the skin and mucosal
membranes affected by Col7 deficiency. Relevant to this and
in contrast to other congenital disorders, such as those affec-
ting DNA repair genes in Fanconi’s anemia (Raya et al., 2009;
Tulpule et al., 2010), Col7 does not seem to be necessary for
stem cell self-renewal and generation of iPS cells.
The complexity of RDEB, as evidenced by a plethora of
biochemical events downstream of the Col7 pathology and by
the varied phenotypes of human disease, is perhaps matched
by the versatility and promise of reprogramming
cell technology (Takahashi and Yamanaka, 2006b; Maherali
et al., 2008b; Park et al., 2008c; Ebert et al., 2009; Vierbuchen
et al., 2010). An unresolved question, however, is whether the
potential risks of iPS cell-derived therapy, such as those related
to the following: (1) the genotoxicity of reprogramming using
embryonic stem cell-specific transcription factors and the
methods by which gene augmentation of mutated genes is
accomplished (e.g., viral vector delivery) (Kohn et al., 2003);
(2) fidelity of acquisition and maintenance of pluripotent
phenotype and lineage-specific cell fates; and (3) cell purity of
the on-demand differentiated iPS cell progeny in the absence
of undifferentiated and potentially tumorigenic iPS cells, can
be minimized or avoided altogether.
Nevertheless, even at present, RDEB iPS cells offer a
model of RDEB disease that is to our knowledge previously
unreported and that may help to understand the pathogenic
cascades underlying the inherent complexity of RDEB. These
insights, and the use of the cellular progeny of gene-corrected
autologous RDEB iPS cells, present an opportunity for future
clinical translation in a manner that may preclude the
immunological complications of allogeneic transplantation.
MATERIALS AND METHODS
Patients
After obtaining written, informed consent as approved by the
Institutional Review Board of the Human Subjects Committee at
the University of Minnesota, skin or marrow cells were collected
from healthy volunteers and from individuals with RDEB. All
procedures adhered to the Helsinki Guidelines.
iPS cells
Detailed methods describing the isolation of FBs and KCs are
included as Supplementary Materials online. For induction of iPS
cells, four reprogramming factors, namely OCT4, SOX2, KLF4,
and c-MYC were used to produce retroviral supernatants. Each of
the viral supernatants was produced by transfecting 293T/17 cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with three
plasmids: one cargo plasmid (containing the reprogramming gene), a
plasmid expressing the VSV-G envelope gene, and a helper plasmid
with the retroviral Gag/Pol gene. The plasmids were obtained from
Addgene (Cambridge, MA). In all, 48 to 72hours after transfection,
Skin-like structures derived from RDEB iPS cellsSkin-like structures derived from wild-type iPS cells
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Figure 5. Skin-like structures derived from WT and RDEB iPS cells. (a–d) K5 (green) and Col7 (red) are coexpressed in WT KC iPS cell-derived teratomas.
(e–h) Similar structures form in RDEB KC iPS cell-derived teratomas, yet Col7 is undetectable. DAPI, 4,6-diamidino-2-phenylindole; iPS cells, induced
pluripotent stem cells; KC, keratinocyte; RDEB, recessive dystrophic epidermolysis bullosa; WT, wild type. Bar¼ 50 mm.
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viral supernatants were harvested, centrifuged at 400 g for
15minutes, and filtered through a 0.45-mm filter.
Approximately 50,000 KCs or 100,000 FBs per well of a 6-well
plate were plated and infected with a 1:1:1:1 mix of retroviral
supernatants of pMIG containing OCT4, SOX2, KLF4, and c-MYC
in the presence of 5 mgml1 of protamine sulfate. Transduction
consisted of a 45-minute spinfection at 1,800 r.p.m. at room
temperature; supernatants were left in contact with the cells for
24 hours at 37 1C and 5% CO2. The next day, cells were spinfected
for a second time. Cells were placed in plates coated using a Coating
Matrix Kit (Cascade Biologics, Portland, OR) and maintained in the
KC medium (EpiLife Medium, Cascade Biologics: 0.06mM calcium
chloride, plus human KC growth supplement) at 37 1C, 5% CO2.
Five days later, cells were trypsinized and seeded onto feeder layers
of irradiated CF1 MEFs. After 24 hours, the medium was changed to
human embryonic stem cell medium, consisting of DMEM/F12
(Invitrogen) supplemented with 10% KnockOut Serum Replacement
(Invitrogen), 2mM GlutaMAX (Invitrogen), 50 mM 2-mercaptoethanol
(Invitrogen), 1 nonessential amino acids (Invitrogen), 50Units
ml1 penicillin, 50mgml1 streptomycin, and 10 ngml1 basic FB
growth factor (R&D Systems, Minneapolis, MN). Cultures were
maintained at 37 1C, 5% CO2, with daily medium changes. Starting
1 week after plating onto MEFs, the medium was supplemented
with 1mM PD0325901 and 1mM CT 99021 (both from Stemgent,
San Diego, CA) for 1 week. Colonies were picked based on
morphology, 30–60 days after the initial infection.
We identified iPS cell colonies using live staining with TRA-1-60
antibody (1:400, Millipore, Billerica, MA) and secondary antibody
Alexa 488-conjugated anti-mouse IgM (1:400, Invitrogen) diluted
in the hES medium, and added into the culture plate. TRA-1-60þ
colonies were identified under a fluorescence microscope (Leica
DMI6000B, Leica, Bannockburn, IL). To confirm that iPS cells were
not contaminated with donor cells, competitive PCR analysis of
variable tandem repeat regions was performed as described
previously (Scharf et al., 1995).
To confirm their cellular phenotype, iPS cells were fixed with 4%
paraformaldehyde for 20minutes. If nuclear permeation was required,
cells were treated with 0.2% TritonX (Sigma-Aldrich, St Louis, MO) in
phosphate-buffered saline (PBS) for 30minutes, blocked in 3% bovine
serum albumin in PBS for 2 hours, and incubated with the primary
antibody overnight at 4 1C. Antibodies targeting the following antigens
were used: TRA1-60 (MAB4360, 1:400), TRA1-81 (MAB4381, 1:400),
stage-specific embryonic antigen-4 (MAB4304, 1:200), and stage-
specific embryonic antigen-3 (MAB-4303, 1:200), all from Chemicon
(Billerica, MA), OCT3/4 (AB27985, 1:200) from Abcam (Cambridge,
MA), and NANOG (EB068601:100) from Everest (Upper Heyford,
Oxfordshire, UK). Cells were incubated with secondary Alexa Fluor
Series antibodies (all 1:500, Invitrogen) for 2 hours at room
temperature and then with DAPI (4,6-diamidino-2-phenylindole)
(1mgml1, Invitrogen) for 10minutes. Images were examined using
a Leica DMI6000B microscope equipped with Q-Imaging Retiga
2000R Camera and Q-Capture software (QImaging, Surrey, BC,
Canada). Direct alkaline phosphatase activity was analyzed as per the
manufacturer’s recommendations (Millipore).
Reverse transcriptase-PCR
RNA was isolated using a GenElute Mammalian Total RNA Miniprep
Kit (Sigma-Aldrich) and treated with TURBO DNA-free (Ambion,
Austin, TX). First-strand cDNA was synthesized using a Superscript
III First-Strand Synthesis SuperMix for quantitative reverse transcrip-
tase-PCR (Invitrogen). Reverse transcriptase-PCR was performed
using TaqMan Gene Expression Assays and TaqMan Universal PCR
Master Mix, No AmpErase UNG (Applied Biosystems, Carslbad, CA)
as per the manufacturer’s protocol.
TaqMan gene expression assays used were Col7a1
(Hs01574733_g1), Col17 (Hs00166711_m1), Ker1 (Hs00196158_m1),
Ker15 (Hs00267035_m1), POU5F1 Hs 00999634_gH; SOX2 Hs
00602736_s1; NANOG Hs 02387400_g1; KLF4 Hs 00358836_m1;
MYC Hs 00153408_m1; LIN28 Hs 00702808_s1; DNMT3 Hs
01003405_m1, with GAPDH (Hs99999905_m1) used as an endo-
genous control. Expression levels were measured in duplicate. For genes
with expression below the CT fluorescence threshold, CT was set at 40
to calculate the relative expression. Analysis was performed using an
ABI PRISM 7500 sequence detection system (Applied Biosystems).
Bisulfite genomic sequencing
Genomic DNA was isolated using a PureLink Genomic DNA Mini
Kit (Invitrogen). Bisulfite treatment was carried out using an EpiTect
Bisulfite kit (Qiagen, Valencia, CA). Converted DNA was PCR
amplified using OCT4- and NANOG-specific primer sets (Freberg
et al., 2007). PCR products were gel purified using a PureLink Quick
Gel Extraction and PCR Purification Combo Kit (Invitrogen), and
cloned into bacteria using the TOPO TA Cloning Kit for Sequencing
(Invitrogen).
Differentiation of iPS cells
Detailed methods describing isolation of hematopoietic differentia-
tion of iPS cells are included as Supplementary Materials online. For
teratoma formation, NOG young adult mice were injected with 1
million cells resuspended in a mixture of DMEM/F12, Matrigel (BD
Biosciences, San Jose, CA), and collagen (ratio 2:1:1, 40 ml per
mouse) into the right quadriceps muscle. Tumors were harvested in
4–8 weeks and cryopreserved at 80 1C in optimal cutting
temperature medium (Sakura Finetek USA, Torrance, CA). Sections
of 6-mm-thickness were cut and mounted on Superfrost Plus glass
slides (Thermo Fisher Scientific, Waltham, MA). Tissues were then
fixed in acetone for 5minutes at room temperature. After rehydrating
the samples in PBS for 5minutes, blocking solution of 10% normal
donkey serum was applied for 1 hour at room temperature. The
tissues were then incubated with mouse anti-human Col7 antibody
(1:250, BD Biosciences), and rabbit anti-human K5 antibody (1:600,
Covance, Emeryville, CA) and then incubated with secondary
antibodies, anti-mouse Cy3 (1:500, Jackson ImmunoResearch, West
Grove, PA), and goat anti-rabbit Alexa Fluor 488 (1:800, Invitrogen).
Tissues were rinsed three times with PBS and coverslipped with
a hardset mounting medium with DAPI (Vector Laboratories,
Burlingame, CA). Optical parameters used for light microscopy are
included as Supplementary Materials online.
Correction of RDEB iPS cells
The COL7A1-COL7A1 expression cassette, in which the full-length
COL7A1 cDNA expression is driven by a short COL7A1 promoter
(Titeux et al., 2010), was cloned into the pEGFP-1 plasmid back-
bone (Clontech, Mountain View, CA) as folows: (1) pEGFP-1
was digested by HindIII and NotI to excise the enhanced
green fluorescent protein (EGFP) open-reading frame, (2) the
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pCMS-COL7A1-COL7A1 retroviral backbone vector (Titeux et al.,
2010) was digested by HindIII and NotI to release the COL7A1–-
COL7A1 expression cassette, and (3) pEGFP-1 (D-EGFP) and 10 kb
COL7A1–COL7A1 fragments were ligated to generate the pCOL7A1-
COL7A1-pA vector (13.4 kb). RDEB iPS cells were nucleofected with
this Col7 cDNA using the Human Stem Cell Nucleofector Kit 1
(program A-023, Amaxa/Lonza, Walkersville, MD) with 1.2mg of
DNA per 1 million cells. Nucleofected cells were plated in
AggreWell plates (StemCell Technologies, Vancouver, BC, Canada).
After 48 hours, embryoid bodies formed and were transferred to four-
chambered glass slides coated with Matrigel. To assess Col7
expression 72 hours after nucleofection, cells were fixed in a 1:1
ratio of ice-cold methanol/acetone for 7minutes, washed with 1
PBS, blocked with 10% normal donkey serum for 1 hour, and stained
with primary Col7 antibody (1:250, BD Biosciences) for 2 hours
at room temperature. Slides were washed and secondary antibody
donkey anti-mouse cy3 (1:500, Jackson Immunoresearch) was
applied for 1 hour. DAPI was added, and slides were imaged by
confocal microscopy using Olympus BX61 FluoView 500 confocal
microscope and FluoView software (Olympus, Center Valley, PA).
Data analysis
Differences between measurements were evaluated using Student’s
t-test, with P-values o0.05 considered significant.
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